STAAR’s next-generation lens, EVO ICL is implanted in the eye, where it works with the patient’s natural eye to repair their vision.
The EVO ICL, unlike traditional lenses, is placed inside the eye between the iris and the natural lens where it can stay for an indefinite period.
The lens is made of Staar Surgical’s patented collamer which is a collagen based material, an organic compound which characterises the lens’ ability to work with the natural lens of the eye.
The EVO ICL, with its central hole, allows enhanced refractive outcomes while ensuring efficiency and comfort for both the patient and the surgeon by eliminating the extra surgical step of the peripheral iridotomy.
STAAR Surgical president and CEO Caren Mason said: "We are very pleased with Health Canada’s approval that allows us to offer the EVO ICL for myopia, with a broad power range of -3.0 to -18.0 diopters, to our surgeons and their patients in Canada.
"This represents an important new treatment option for eligible patients between 21 and 45 years old living with nearsightedness.
"This approval reinforces our deep commitment to patients seeking visual freedom, as we continue to build our growing EVO ICL portfolio."
The EVO ICL has recently exhibited its functionality at the American Society of Cataract and Refractive Surgery (ASCRS) meeting earlier this month in the US as part of the Evolution of Visual Freedom initiative.
About 200,000 lenses from the EVO ICL genre have been implanted across the world till date.